← Protara Therapeutics, Inc. (TARA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Protara Therapeutics, Inc. (TARA)
Biological Products, (No Diagnostic Substances) · market cap $207M · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
2
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Protara Therapeutics (TARA) is a clinical-stage biotech with 28 employees and a ~$236M market cap, built around two assets: Choline Chloride for Injection in Phase 3 for Choline Deficiency and TARA-002 in Phase 2 for Non-muscle Invasive Bladder Cancer. The company carries only $14.7M in cash, representing roughly 2.1 months of runway, making near-term dilution an acute structural concern ahead of a pivotal Phase 3 readout estimated for June 2027.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Choline Chloride for Injection | Phase 3 | Choline Deficiency |
| TARA-002 | Phase 2 | Non-muscle Invasive Bladder Cancer |
Price & technical context
3-month
-35.0%
6-month
-48.1%
12-month
-39.9%
52-wk range
$2.65–$7.56
vs 50-day MA
-29.8%
vs 200-day MA
-45.3%
Realized vol
76.6%
Max drawdown
-64.9%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TARA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.